Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: A suicide assessment methodology study report

Diane Warden, Madhukar H. Trivedi, Stephen R. Wisniewski, Benji Kurian, Sidney Zisook, Susan G. Kornstein, Edward S. Friedman, Sachiko Miyahara, Andrew F. Leuchter, Maurizio Fava, A. John Rush

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume30
Issue number3
DOIs
StatePublished - Jun 2010

Fingerprint

Serotonin Uptake Inhibitors
Suicide
Therapeutics
Major Depressive Disorder
Outpatients

Keywords

  • Adherence
  • Adverse events
  • Antidepressant
  • Attrition
  • Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Early adverse events and attrition in selective serotonin reuptake inhibitor treatment : A suicide assessment methodology study report. / Warden, Diane; Trivedi, Madhukar H.; Wisniewski, Stephen R.; Kurian, Benji; Zisook, Sidney; Kornstein, Susan G.; Friedman, Edward S.; Miyahara, Sachiko; Leuchter, Andrew F.; Fava, Maurizio; Rush, A. John.

In: Journal of Clinical Psychopharmacology, Vol. 30, No. 3, 06.2010, p. 259-266.

Research output: Contribution to journalArticle

Warden, D, Trivedi, MH, Wisniewski, SR, Kurian, B, Zisook, S, Kornstein, SG, Friedman, ES, Miyahara, S, Leuchter, AF, Fava, M & Rush, AJ 2010, 'Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: A suicide assessment methodology study report', Journal of Clinical Psychopharmacology, vol. 30, no. 3, pp. 259-266. https://doi.org/10.1097/JCP.0b013e3181dbfd04
Warden, Diane ; Trivedi, Madhukar H. ; Wisniewski, Stephen R. ; Kurian, Benji ; Zisook, Sidney ; Kornstein, Susan G. ; Friedman, Edward S. ; Miyahara, Sachiko ; Leuchter, Andrew F. ; Fava, Maurizio ; Rush, A. John. / Early adverse events and attrition in selective serotonin reuptake inhibitor treatment : A suicide assessment methodology study report. In: Journal of Clinical Psychopharmacology. 2010 ; Vol. 30, No. 3. pp. 259-266.
@article{4dd0b8812d22465ca4f3a941fb93d97b,
title = "Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: A suicide assessment methodology study report",
abstract = "Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment.",
keywords = "Adherence, Adverse events, Antidepressant, Attrition, Depression",
author = "Diane Warden and Trivedi, {Madhukar H.} and Wisniewski, {Stephen R.} and Benji Kurian and Sidney Zisook and Kornstein, {Susan G.} and Friedman, {Edward S.} and Sachiko Miyahara and Leuchter, {Andrew F.} and Maurizio Fava and Rush, {A. John}",
year = "2010",
month = "6",
doi = "10.1097/JCP.0b013e3181dbfd04",
language = "English (US)",
volume = "30",
pages = "259--266",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Early adverse events and attrition in selective serotonin reuptake inhibitor treatment

T2 - A suicide assessment methodology study report

AU - Warden, Diane

AU - Trivedi, Madhukar H.

AU - Wisniewski, Stephen R.

AU - Kurian, Benji

AU - Zisook, Sidney

AU - Kornstein, Susan G.

AU - Friedman, Edward S.

AU - Miyahara, Sachiko

AU - Leuchter, Andrew F.

AU - Fava, Maurizio

AU - Rush, A. John

PY - 2010/6

Y1 - 2010/6

N2 - Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment.

AB - Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n = 265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific adverse effects were evaluated with the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, and at week 2, the Frequency, Intensity, and Burden of Side Effects Rating globally assessed adverse effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 adverse effect, either treatment-emergent or with worsening intensity, was independently associated with attrition. Global ratings of adverse effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment.

KW - Adherence

KW - Adverse events

KW - Antidepressant

KW - Attrition

KW - Depression

UR - http://www.scopus.com/inward/record.url?scp=77952325101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952325101&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181dbfd04

DO - 10.1097/JCP.0b013e3181dbfd04

M3 - Article

C2 - 20473060

AN - SCOPUS:77952325101

VL - 30

SP - 259

EP - 266

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -